News
23h
Barchart on MSNDan Ives Says Palantir Is on a ‘Golden Path.’ Does That Make PLTR Stock a Buy Here?Palantir (PLTR) shares are in focus on Thursday after a senior Wedbush analyst, Dan Ives, issued a positive note in favor of ...
Dan Ives has raised his price target for Palantir Technologies, signaling a 12% upside from its trading price over the next ...
1d
Investor's Business Daily on MSNPalantir Slips. Bull Points To 'Bears In The Hibernation Cave'Palantir stock slips as Wedbush analyst Dan Ives points to "bears in the hibernation cave" who worry about valuation.
Palantir's stock has been one of the biggest beneficiaries of the AI boom this year, with one longtime bull expecting it ...
Dan Ives of Wedbush, in an interview with Bloomberg, predicted a strong second half for technology stocks, calling this the ...
Veteran Wedbush analyst Dan Ives said he thinks Palantir Technologies (PLTR 0.77%) is one of the undiscovered gems in this AI gold rush, calling the company the "Messi of AI." ...
Ives highlighted that Palantir is involved in “75 to 80 large AI enterprise deals”, with contracts typically ranging from $3-5 million, and some even reaching eight figures over multiple years.
Dan Ives of Wedbush Securities recently took to social media to proclaim that Palantir AIP is the "launching pad of AI use cases." His latest research report places a price target of $35 on ...
Palantir stock is a top AI play that's undervalued by Wall Street, Wedbush analyst Dan Ives said. Ives pointed to deals with government agencies and businesses to back up his $50 per share bull ...
Dan Ives, Managing Director and Senior Equity Analyst at Wedbush Securities, shares his expert insights on the future of AI, Big Tech, and stock market trends in 2025.
Dan Ives has doubled down on his earlier claims that Palantir will hit a $1 trillion valuation, even though Wall Street enthusiasm was damp after Q1 earnings.
Dan Ives of Wedbush Securities recently took to social media to proclaim that Palantir AIP is the "launching pad of AI use cases." His latest research report places a price target of $35 on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results